MARINOMED BIOTECH AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.7 EUR | 0.00% |
|
-4.57% | -42.81% |
| 16/04 | Transcript : Marinomed Biotech AG, 2023 Earnings Call, Apr 16, 2024 | |
| 16/04 | Marinomed Biotech AG Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- The company's profit outlook over the next few years is a strong asset.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company has insufficient levels of profitability.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 53.87 times its estimated earnings per share for the ongoing year.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -42.81% | 27.71M | - | ||
| -3.79% | 88.14B | A- | ||
| +1.45% | 40.51B | A- | ||
| -15.94% | 31.67B | B- | ||
| +52.66% | 24.62B | A | ||
| -14.50% | 15.65B | C | ||
| -9.12% | 11.97B | D+ | ||
| -14.38% | 12.07B | B- | ||
| -42.56% | 11.61B | B | ||
| +4.87% | 8.81B | B+ |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- MARI Stock
- Ratings Marinomed Biotech AG
